BioVectra wins contract to make Prolanta for trials
Canadian biologics CMO BioVectra has been contracted to make trial supplies of the candidate cancer treatment Prolanta by US biopharmaceutical firm Oncolix.
BioVectra will manufacture the active pharmaceutical ingredient (API) for Phase II trials due to commence in Q2 next year and has agreed to invest C$1.5m (EUR939,349) in Texas-based Oncolix.
Dale Zajicek, BioVectra’s COO, said that: “Oncolix needed to identify a partner with a unique set of fermentation and downstream processing skills who was also willing to customize a scale-up plan, efficiently and effectively under the required regulations.”
Oncolix CEO Michael Redman explained that: “We chose BioVectra as our contract manufacturer because of their ability to produce cGMP manufacturing of Prolanta from shaker flask, to small-scale to full commercial production.”
